A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
An important trial by Schwartzberg et al. has recently been published in The Oncologist. In prospective manner, this trial tested the two erythropoietin preparations commonly used in the US, epoetin alfa and darbepoetin alfa, in their most commonly used doses and schemas in anemic cancer patients on chemotherapy. The two drugs performed with remarkably similar […]
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
A nicely done placebo controlled trial of darbepoetin in anemic hematologic malignancy patients demonstrating darbepoetin’s efficacy and safety. – David H. Henry